Germline <i><scp>BAP1</scp></i> mutations predispose also to multiple basal cell carcinomas
Arnaud de la Fouchardière(Université Claude Bernard Lyon 1), Brigitte Bressac–de Paillerets(Institut Gustave Roussy), Clotilde Penet(L’Institut du Cancer Courlancy Reims), H. Schvartz(Centre de Neurophysique Physiologie et Pathologie), P. Combemale(Centre Léon Bérard), Nadem Soufir(Inserm), Odile Cabaret(Institut Gustave Roussy), Valérie Bonadona(Centre Léon Bérard), Leonid T. Savin(L’Institut du Cancer Courlancy Reims)
Cited by 98
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Mutational spectrum in a worldwide study of 29,700 families with<i>BRCA1</i>or<i>BRCA2</i>mutations
|Human Mutation|2018|319
Genome-wide association study identifies three new melanoma susceptibility loci
|Nature Genetics|2011|250
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194